April 22, 2022 7:45am

Many CEOs have forgotten their investors as a relationship that needs to be coddled, not taken for granted

Pre-open indications: NONE - Upside or Downside indications and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

It’s Friday after a crap (1 positive and 3 negative closes) week, do you expect much – I’m not expecting much if any positioning

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.23% (-80 points), S&P futures are DOWN -0.13% (-5 points) and NASDAQ futures are DOWN - -0.02% (-3 points) early in the pre-open


Stock futures were mixed in early morning trading Friday after Fed Chair Powell said a half-percentage (0.50%) point rate hike is “on the table” for next month,

European stocks fell in early trading after a dramatic reversal in stock markets in the U.S. Thursday

Asia-Pacific stocks were largely lower, while Mainland China Australia and South Korea were lower.



Indexes are coming off a mixed session Wednesday and falling Thursday in a sharp reversal, as a jump in Treasury yields offset the optimism coming from new earnings’ reporting.

From last night, the Dow closed DOWN -368.03 points (-1.05%); the S&P closed DOWN -65.79 points (-1.48%) while the Nasdaq closed DOWN -278.41 points (-2.07%).

For this week, the Dow is up 1% and on pace to break a three-week losing streak. The S&P is up less than 0.1% on the week and attempting to break a two-week losing streak. The Nasdaq, however, is down 1.3% week to date, on track to post its third negative week in a row. <CNBC>


Last night’s RegMed Investors’ (RMi) closing bell post: market conditions and sector sentiment are hammered” … https://www.regmedinvestors.com/articles/12399

Ebb and flow –

Q2/22 –1 holiday, 4 positive and 10 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS



Pimp/Pump and Promote:

Biostage (BSTG) closed up +$0,90 with 771 shares traded after Wednesday’s -$0.48 to $5.50 with 1,131 shares traded, Tuesday’s +$0.48 with 1,168 shares traded, Monday -$0.48 with 2,873 shares traded and last Thursday’s -$0.02 to $5.98.

  • WARNING:  WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.


The BOTTOM LINE: Weak aftermarkets, openings and even weaker closes are hallmarks of the cell and gene therapy sector.

These recent, ugly market setbacks serve as a warning to investors to reduce exposure.

Be wary of early morning moves, breakouts and especially cell and gene therapy stocks.

I try to keep it simple … and short!

To expect a payday; volatility and low volume are part of the equation which could set-up BUY/SELL opportunities.

Investors should consider taking at least partial profits quickly on winners to avoid round-tripping moves.

I am still, in the here and now, the cell and gene therapy sector will continue to “flutter”; we are about to enter the earnings’ zone!

  • Earnings’ season is upon us as Alnylam Pharmaceuticals (ALNY) reports Thursday, 4/28 followed so far by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN), Ionis Pharmaceuticals (IONS), MiMedx (MDXG) and Vericel (VCEL) on 5/4 so far.


RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.